Review of: "A Value-Driven Future Approach to Precision Medicine for Health Sustainability in New Zealand: A Perspective"

Sanaz Nargesi

Potential competing interests: No potential competing interests to declare.

This manuscript holds promising prospects for patients utilizing precision medicine.

In the section referring to application of precision medicine in respiratory diseases, it may be better to mention the cystic fibrosis disease as well. This is due to the estimation that over 80 thousand individuals worldwide are affected by this disease. A primary and significant objective of personalized medicine could involve the utilization of optimal and practical tests to track **genomic variations** in the CFTR gene, in order to identify noteworthy mutations and implement intelligent treatments. Subsequent to this, the **analysis of biomarkers** associated with inflammatory conditions observed in cystic fibrosis, such as TNF-α and IL8, in respiratory samples, may unveil a distinct panel specific to patients. This can facilitate a smoother treatment trajectory. Ultimately, the development of personalized **drug delivery systems** that are tailored exclusively to the anatomical structure and lung capacity of the afflicted individual can be regarded as an ideal therapeutic approach.

It is proposed that in relation to each of the diseases that have been discussed, the authors provide an elaborate citation specifying the designations of the alleles in which the mutation has occurred, alongside further comprehensive elucidations concerning the strategies employed for treatment.